Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Beeley
Antony Hugh Beeley, Siesta Park AU
| Patent application number | Description | Published |
|---|---|---|
| 20110046544 | APPARATUS AND METHOD FOR RELEASING A MASS FROM A BIOLOGICAL CAVITY - An apparatus ( | 02-24-2011 |
| 20110112557 | APPARATUS AND METHOD FOR LAPAROSCOPIC PORT SITE SUTURE - A surgical device for guiding a needle during suturing of an incision comprising a body for insertion in the incision having a first passage to conduct an end of the needle below a location surrounding the incision, wherein a distal portion of the body comprises means for indicating the location to which the needle will be conducted. Methods for suturing an incision using the surgical device are also provided. | 05-12-2011 |
Nathan R.f. Beeley, Santa Barbara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100189765 | IMPLANTABLE OCULAR DRUG DELIVERY DEVICE AND METHODS - The present invention provides implantable ocular drug delivery devices. Generally, the devices have a distal portion with a coil shaped body member and a proximal portion which contacts the sclera. In one aspect, the coil-shaped body member includes a unique configuration including two coiled portions with different pitches, which improves insertion of the device into the eye. In another aspect, the device has a proximal portion that includes a unique cap configuration having a concave distal face that improves stabilization of the device in the eye. In another aspect, the device includes a transitional portion between the cap and the coil-shaped body member that also improves stabilization of the device in the eye. The invention also provides methods for inserting the medical device into the eye, and methods for the treatment of an ocular condition. | 07-29-2010 |
| 20110251568 | PUNCTAL PLUGS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS - Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured for controlled release into the eye by means of an osmotic engine. | 10-13-2011 |
Nathan R. F. Beeley, Santa Barbara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120059338 | PUNCTAL PLUG CONTAINING DRUG FORMULATION - Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye and is configured for release medication via a designated port, valve, or orifice in the insert housing and inhibits diffusion of medication via the housing itself. | 03-08-2012 |
Nigel R.a. Beeley, Solana Beach, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110195904 | METHODS OF TREATMENT USING EXENDIN PEPTIDES OR GLP-1 PEPTIDES - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 08-11-2011 |
Nigel R.a. Beeley, San Deigo, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090054341 | Methods of Treatment Using Exendin Peptides or GLP-1 Peptides - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 02-26-2009 |
Nigel Robert Arnold Beeley, Solana Beach, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090176704 | Exendin Agonist Analogs to Treat Diabetes - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 07-09-2009 |
Nigel Robert Arnold Beeley, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090029913 | Novel exendin agonist compounds - Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying. | 01-29-2009 |
| 20110071076 | NOVEL EXENDIN AGONIST COMPOUNDS - Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying. | 03-24-2011 |